Astellas Pharma, The Current Fiscal Year Net Income Revised Downward to an Unexpected 18% Decrease

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Jan 24, 2025 4:00 pm JST Revision

4503 Astellas Pharma Inc. 【IFRS】

Guidance Update Report

Astellas Pharma Inc. <4503> [TSE Prime] announced a performance revision after the market closed on January 24th (16:00). The consolidated net income for the fiscal year ending March 2025 has decreased 72.0%, from the previous forecast of 50 billion yen to 14 billion yen (compared to 17 billion yen in the previous period). This changes the outlook from an anticipated profit increase to a projection of a 17.9% decrease in profit.

Based on the downwardly revised full-year plan announced by the company, our calculation indicates that the October to March period (2H) consolidated net income/loss has been revised downward from an expected loss of 23.5 billion yen to a loss of 59.5 billion yen (compared to a loss of 18.7 billion yen in the same period of the previous year), indicating an expansion in the loss margin.

Kabutan News

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	864,379	-13,710	-19,042	-23,511	-13.1	37	Oct 30, 2024	IFRS
Oct - Mar, 2024 New	964,379	-82,710	-88,042	-59,511	-33.2	37	Jan 24, 2025	IFRS
Revision Rate	+11.6%	-503.3%	-362.4%	-153.1%	-153.2%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	1,800,000	80,000	70,000	50,000	27.9	74	Oct 30, 2024	IFRS
Mar, 2025 New	1,900,000	11,000	1,000	14,000	7.8	74	Jan 24, 2025	IFRS
Revision Rate	+5.6%	-86.3%	-98.6%	-72.0%	-72.0%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	836,534	-29,638	-31,349	-18,765	-10.5	35	Apr 25, 2024	IFRS
Oct - Mar, 2024 Guidance	964,379	-82,710	-88,042	-59,511	-33.2	37	Jan 24, 2025	IFRS
YoY	+15.3%	-179.1%	-180.8%	-217.1%	-217.5%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	1,518,619	133,029	132,361	98,714	54.2	60	Apr 27, 2023	IFRS
Mar, 2024	1,603,672	25,518	24,969	17,045	9.5	70	Apr 25, 2024	IFRS
Mar, 2025 Guidance	1,900,000	11,000	1,000	14,000	7.8	74	Jan 24, 2025	IFRS
YoY	+18.5%	-56.9%	-96.0%	-17.9%	-17.8%